circulating tumor DNA
Natera Builds Data Backing Serial ctDNA Changes to Aid CRC Patient Management, Treatment Decisions
Premium
The company believes its findings are the first to show that quantifying ctDNA changes can stratify high-risk colorectal cancer patients into better and worse prognostic groups.
Personal Genome Diagnostics, Cleveland Clinic Join Forces to Advance Liquid Biopsy
Leaders from collaborating Cleveland Clinic institutes will work with PGDx to optimize its ctDNA test reporting and adapt its technology for new oncology applications.
Molecular Health, Eone-Diagnomics Genome Center Ink Liquid Biopsy Partnership
EDGC will use Molecular Health's genomics interpretation software to provide circulating tumor DNA sequencing test results for cancer precision medicine.
Cell-Free DNA Can Help Predict Pathological Complete Response, Gauge Minimal Residual Disease
A suite of new studies examined how liquid biopsies could personalize treatment strategies in a range of cancer types.
Blood Testing Distinguishes Benign Tumors From Precancerous Condition
Researchers used ultra-low-pass whole genome sequencing and cell-free DNA fragment size selection to detect pre-cancer in neurofibromatosis type 1 patients.